239 studies found for:
Open Studies | "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 1 | Recruiting |
Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate
|
||||
| 2 | Recruiting |
Donor Umbilical Cord Blood Transplant With or Without Ex-Vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes
|
||||
| 3 | Recruiting |
Fludarabine Phosphate and Total-Body Irradiation Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
|
||||
| 4 | Recruiting |
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
|
||||
| 5 | Recruiting |
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
|
||||
| 6 | Recruiting |
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
|
||||
| 7 | Recruiting |
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
|
||||
| 8 | Recruiting |
Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
|
||||
| 9 | Recruiting |
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
|
||||
| 10 | Recruiting |
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant For Hematologic Cancer
|
||||
| 11 | Recruiting |
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
||||
| 12 | Not yet recruiting |
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
|
||||
| 13 | Recruiting |
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease
|
||||
| 14 | Recruiting |
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
|
||||
| 15 | Recruiting |
Sirolimus, Tacrolimus, Anti-Thymocyte Globulin, and Rituximab in Preventing Graft-versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
|
||||
| 16 | Recruiting |
Computer-Guided Glucose Management Systems in Treating Patients With Hyperglycemia Who Have Undergone Blood and Bone Marrow Transplant
|
||||
| 17 | Recruiting |
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
|
||||
| 18 | Recruiting |
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
|
||||
| 19 | Not yet recruiting |
Selectively T Cell Depleted Donor Peripheral Blood Stem Cell Transplant in Preventing Graft-Versus-Host Disease in Younger Patients With High Risk Hematologic Malignancies
|
||||
| 20 | Recruiting |
Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer
|
† Indicates status has not been verified in more than two years
